Cila Therapeutics

CILA THERAPEUTICS is dedicated to respiratory health and focused on innovative treatments to help patients breathe easily and protect their lungs from irreversible damage. We own 100% of the robust IP portfolio that will generate value for investors and patients through the development of: 1. First-in-class, novel, inhaled therapeutics (de-risked) for the treatment of Airway Obstructive Pulmonary Diseases (AOPD) including COPD, Bronchiectasis, severe Asthma, Cystic fibrosis, and more to address a critical unmet need for ~20 million patients in the US and > 200 million globally. Our lead candidate CIL-05 can enter clinical studies in 12 months for our first indication, Primary Ciliary Dyskinesia (PCD), an orphan genetic disease. The path to approval is clearly defined after pre-IND meetings with the FDA. A co-therapy platform to improve the transfection efficiency of nucleic acid therapeutics (RNA, DNA) and enhance delivery to lung and airway cells, increasing the efficacy and safety of these therapeutics for lung diseases, including Lung Cancer and Pulmonary Fibrosis CILA’s team has a successful track record with broad and diverse experience in patient care, drug discovery, development, manufacturing, commercialization, and reimbursement. The team is well-equipped to navigate drug development challenges and bring innovative therapies to market, positioning CILA Therapeutics as a leader in respiratory medicine.